Transition Leadership Announcement
The voice of people with narcolepsy is the heart of Narcolepsy Network. Since we announced leadership changes in February, we are continuing to deliver on current programs […]
Virtual Mini-Conferences
Join us for our next free Virtual Mini-Conference, which will be held on Saturday, April 24 at 2:00 PM ET/11:00 AM PT. The theme will be Finding Your […]
Become a Member for $5! Limited Time Offer!
Join Narcolepsy Network for $5Limited offer now through January 31, 2021 For a limited time, we are lowering our individual annual membership dues to $5. Now is […]
Donate to Make Twice the Impact
Thanks to a few generous donors, if you make a donation before January 1, 2021, they will match your gift up to $10,000. This means your donation […]
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
Avadel Pharmaceuticals plc announced the submission of its New Drug Application to the US Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium […]
Mini-Conference Webinar: I Was Just Diagnosed: Now What?
Our second Virtual Mini-Conference webinar was held on December 5. The theme was I Was Just Diagnosed: Now What? and focused on topics for those starting out […]
Support Us on #GivingTuesday
This year has been one to remember! While many of us are still struggling to find a new normal, we are proud of the programs we have […]
Mindfulness Meditation Program Study
If you have been diagnosed with narcolepsy and struggle with depression or anxiety, you may qualify for a study. The Behavioral Sleep Medicine Lab at Northwestern is […]
Mini-Conference Webinar: Legal Issues and Narcolepsy
We kicked off our first Virtual Mini-Conference series on October 17, 2020. We will host a total of five virtual mini-conferences to cover the topics that were […]
RESTORE Study of FT218
If you or your child are over 16 and have been diagnosed with narcolepsy, you may qualify for the RESTORE research study. Managing your narcolepsy symptoms is […]
